|Bid||0.0000 x 3100|
|Ask||0.0000 x 2200|
|Day's Range||0.7751 - 1.1700|
|52 Week Range||0.1510 - 9.7500|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.50|
SAN DIEGO and PLANEGG-MARTINSRIED, Germany, April 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq:IMUX), today announced the completion of its stock-for-stock exchange transaction with Vital Therapies, Inc. (Nasdaq: VTL, through April 12, 2019). The company has been renamed Immunic, Inc. and its common stock is expected to commence trading on The Nasdaq Capital Market under the ticker symbol "IMUX" on April 15, 2019.
Vital Therapies, Inc. (Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to facilitate the closing of the Company’s transaction with Immunic AG. As previously announced, the transaction has been approved by the stockholders of the Company and is expected to be consummated by mid-April.
NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vital Therapies, Inc. (VTL) is a biotherapeutic company, focused on developing cell-based therapies for the treatment of acute forms of liver failure. Vital Therapies announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held Friday. On Friday, April 5, 2019, VTL shares opened at $.26 per share and reached a high of $.70 per share before closing at $.51 on traded volume of 154.5 million shares.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...
Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held earlier today. Approximately 98.82% of the shares voted at the special stockholder meeting voted in favor of the Exchange Agreement proposal, with each of the other related proposals also receiving sufficient votes for approval. “We truly appreciate the support we have received from our stockholders for this transformational combination with Immunic,” said Duane Nash, President and Chief Executive Officer of Vital Therapies.
Vital Therapies, Inc. (VTL) would like to thank its stockholders for their support of the proposed business combination with Immunic AG and remind those stockholders that have not yet voted to vote without delay “FOR” the business combination and the other proposals in the Company’s proxy statement/prospectus for the special meeting of its stockholders to be held on April 4, 2019 at 9:00 a.m. Pacific Time. “The overwhelming majority of Vital Therapies stockholders who have submitted their votes have voted in favor of the transaction. However, more votes are needed to meet the required threshold for the business combination to be completed,” stated Duane Nash, President and Chief Executive Officer of Vital Therapies.
Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Vital Therapies stockholders vote “FOR” the proposed business combination with Immunic AG and the related proposals in the Company’s proxy statement/prospectus for the special meeting of its stockholders to be held on April 4, 2019 at 9:00 a.m. Pacific Time.
Vital Therapies, Inc. (VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the year ended December 31, 2018. On January 6, 2019, we entered into an exchange agreement (the “Exchange Agreement”), with Immunic AG, or Immunic, and all of the current shareholders of Immunic. Under this agreement, all Immunic shareholders will exchange all of their Immunic shares for shares of our common stock, with the result of Immunic becoming a wholly-owned subsidiary of Vital Therapies (the “Transaction”). Concurrently, Immunic’s shareholders entered into an agreement with Immunic, under which, subject to the terms and conditions of such agreement, they will invest an aggregate amount of approximately €26.7 million, or US $30.5 million, in Immunic prior to the consummation of the Transaction.
NEW YORK , Feb. 26, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
SAN DIEGO and PLANEGG-MARTINSRIED, Germany, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL), and Immunic AG (Immunic), a private clinical-stage biotechnology company in Planegg-Martinsried, Germany, today announced that they have entered into a definitive agreement under which Vital Therapies is expected to acquire all of the outstanding shares in Immunic in exchange for newly issued shares of Vital Therapies in an all-stock transaction. The company will focus on advancing Immunic‘s pipeline of novel and potentially transformative treatments for chronic inflammatory and autoimmune diseases.
On a per-share basis, the San Diego-based company said it had a loss of 28 cents. In the final minutes of trading on Wednesday, the company's shares hit 35 cents. A year ago, they were trading at $5.80. ...
SAN DIEGO, Nov. 07, 2018 -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute.
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference. Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading.
Every investor in Vital Therapies Inc (NASDAQ:VTL) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...
Investors need to pay close attention to Vital Therapies (VTL) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / September 13, 2018 / Bausch Health Companies together with Salix's licensors Cedars-Sinai Medical Center and Alfasigma SpA resolve the outstanding intellectual property litigation ...
The San Diego-based company said it had a loss of 30 cents per share. Vital Therapies shares have increased 45 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares ...
Top-line data from Vital Therapies’ study on the treatment of liver failure is expected to be released in September, Xu said in a Monday note. About 60 percent of sAAH patients are younger patients without renal failure or severe coagulopathy, which are part of the main inclusion criteria for VTL-308.